Site icon Market Globalist

Abeona Therapeutics Inc. (ABEO) stock plunged during pre-market. Let’s see why?

Abeona Therapeutics Inc. (NASDAQ: ABEO) stock gained by 14.71% at the last close whereas the ABEO stock price declines by 1.92% in the pre-market trading session. Abeona Therapeutics is a biopharmaceutical firm in the early stages of development that is working on gene and cell therapy for serious diseases.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Financial Highlights.

On May 18, 2021, Abeona Therapeutics announced its first-quarter 2021 financial results. The summary is stated below:


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Michael Amoroso, Chief Executive Officer of Abeona commented:

In 2021, ABEO is off to a flying start, owing to the laser-like emphasis on execution. ABEO is concentrating on finishing participation in the EB-101 Phase 3 pivotal VIITAL trial, determining a regulatory course for ABO-102 in MPS IIIA, delivering the first lot of Abeona-produced therapeutic grade ABO-102, and documenting additional neurocognitive and biomarker results from both the ABO-102 Transpher A and ABO-101 Transpher B trials. ABEO already has a strong preclinical pipeline, and they’re working on evaluating AAV capsids in order to start IND-enabling trials in two to three eye indications.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Exit mobile version